| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
13,960,000 |
| Market
Cap: |
20.94(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6501 - $2.3 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Iterum Therapeutics is a clinical-stage pharmaceutical company focused on developing and commercializing sulopenem oral to be an oral penem available in the U.S. and an oral and intravenous (IV) branded penem available globally. The objective of Co.'s sulopenem program is to deliver to patients an oral and IV formulation of sulopenem approved in the U.S. and Europe for the treatment of infections due to resistant gram-negative pathogens. Co. has also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
65,000 |
65,000 |
75,000 |
| Total Buy Value |
$0 |
$109,995 |
$109,995 |
$132,195 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
4 |
4 |
5 |
| Total Shares Sold |
0 |
0 |
0 |
118,909 |
| Total Sell Value |
$0 |
$0 |
$0 |
$243,022 |
| Total People Sold |
0 |
0 |
0 |
2 |
| Total Sell Transactions |
0 |
0 |
0 |
10 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Matthews Judith M. |
Chief Financial Officer |
• – – |
2021-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
62,500 |
62,500 |
|
- |
|
| Fishman Corey N. |
President & CEO |
• • – |
2021-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
167,500 |
407,453 |
|
- |
|
| Dunne Michael W. |
Director |
– • – |
2021-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
80,000 |
289,498 |
|
- |
|
| Dunne Michael W. |
Chief Scientific Officer |
• – – |
2020-10-27 |
4 |
B |
$0.00 |
$0 |
D/D |
61,540 |
209,498 |
2.66 |
196% |
|
| Matthews Judith M. |
Chief Financial Officer |
• – – |
2020-09-30 |
4 |
AS |
$1.64 |
$92,053 |
D/D |
(56,130) |
0 |
|
160% |
|
| Chin Mark |
Director |
– • – |
2020-07-28 |
4 |
D |
$0.00 |
$0 |
D/D |
(11,857) |
0 |
|
- |
|
| Heron Patrick J |
Director |
– • – |
2020-07-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,852 |
9,006 |
|
- |
|
| Chin Mark |
Director |
– • – |
2020-07-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,703 |
11,857 |
|
- |
|
| Hunt Ronald |
Director |
– • – |
2020-07-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,703 |
5,703 |
|
- |
|
| Kelly David George |
Director |
– • – |
2020-06-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,406 |
37,108 |
|
- |
|
| Powell Michael |
10% Owner |
– – • |
2020-06-02 |
4 |
S |
$1.61 |
$642,960 |
D/D |
(400,000) |
1,226,514 |
|
41% |
|
| Powell Michael |
10% Owner |
– – • |
2020-06-01 |
4 |
S |
$1.69 |
$169,120 |
D/D |
(100,000) |
1,626,514 |
|
41% |
|
| Chin Mark |
Director |
– • – |
2020-04-07 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,089,903) |
0 |
|
- |
|
| Healy James |
Director |
– • • |
2019-05-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,154 |
6,154 |
|
- |
|
| Edick Paul R |
Director |
– • – |
2019-05-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,154 |
31,390 |
|
- |
|
| Chin Mark |
Director |
– • – |
2019-05-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,154 |
6,154 |
|
- |
|
| Ahrens Brenton Karl |
Director |
– • – |
2019-05-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,154 |
6,154 |
|
- |
|
| Heron Patrick J |
Director |
– • • |
2019-05-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,154 |
6,154 |
|
- |
|
| Kelly David George |
Director |
– • – |
2019-05-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,154 |
25,702 |
|
- |
|
| Kelly David George |
Director |
– • – |
2018-11-30 |
4 |
B |
$6.29 |
$62,887 |
D/D |
10,000 |
19,548 |
2.39 |
- |
|
| Chin Mark |
Director |
– • – |
2018-10-30 |
4 |
B |
$6.10 |
$353,800 |
I/I |
58,000 |
1,089,903 |
2.1 |
- |
|
| Dunne Michael W. |
Chief Scientific Officer |
• – – |
2018-09-04 |
4 |
B |
$10.00 |
$5,000 |
D/D |
500 |
147,958 |
2.74 |
- |
|
| Dunne Michael W. |
Chief Scientific Officer |
• – – |
2018-08-27 |
4 |
B |
$10.00 |
$5,000 |
D/D |
500 |
147,458 |
2.74 |
- |
|
| Dunne Michael W. |
Chief Scientific Officer |
• – – |
2018-08-24 |
4 |
B |
$10.00 |
$5,000 |
D/D |
500 |
146,958 |
2.74 |
- |
|
| Edick Paul R |
Director |
– • – |
2018-08-23 |
4 |
B |
$10.44 |
$5,219 |
D/D |
500 |
25,236 |
2.39 |
- |
|
102 Records found
|
|
Page 3 of 5 |
|
|
0.02 (1.32%) 
